BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27040705)

  • 1. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drug profile: cyclin-dependent kinase inhibitors.
    Blachly JS; Byrd JC
    Leuk Lymphoma; 2013 Oct; 54(10):2133-43. PubMed ID: 23488658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.
    Węsierska-Gądek J; Kramer MP
    Future Med Chem; 2012 Mar; 4(4):395-424. PubMed ID: 22416772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Investig Drugs; 2016 Jun; 25(6):729-34. PubMed ID: 26998706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transduction inhibitors in chronic lymphocytic leukemia.
    Ma S; Rosen ST
    Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
    Balakrishnan A; Vyas A; Deshpande K; Vyas D
    World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
    Zeidner JF; Karp JE
    Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase modulators and cancer therapy.
    Gallorini M; Cataldi A; di Giacomo V
    BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
    Decker T; Schneller F; Hipp S; Miething C; Jahn T; Duyster J; Peschel C
    Leukemia; 2002 Mar; 16(3):327-34. PubMed ID: 11896535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
    Robak P; Robak T
    Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.
    Węsierska-Gądek J; Maurer M
    Curr Pharm Des; 2011; 17(3):256-71. PubMed ID: 21348827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
    Sanhes L; Tang R; Delmer A; DeCaprio JA; Ajchenbaum-Cymbalista F
    Leukemia; 2003 Jun; 17(6):1104-11. PubMed ID: 12764376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.